For instance, intraventricular injections of recombinant TPP1 or TPP1-encoding AAV vectors significantly delayed onset and progression of the brain pathology in a CLN2 canine model90,91, but had no therapeutic impact on the progression of retinal degeneration and visual deterioration92. Here, TPP1 is linked to retinal degeneration.